Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Nektar Therapeutics    NKTR

News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Nektar Therapeutics : Announces Data Presentations at ASCO 2017

share with twitter share with LinkedIn share with facebook
share via e-mail
05/25/2017 | 09:03pm CEST

By a News Reporter-Staff News Editor at Clinical Trials Week -- Nektar Therapeutics (Nasdaq: NKTR) announced its presence at the upcoming 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, where it will share updated data from clinical studies of NKTR-214. ASCO will take place June 2-6, 2017 in Chicago (see also Biotechnology Companies).

NKTR-214 is an investigational immuno-stimulatory therapy designed to expand specific cancer-fighting CD8+ effector T cells and natural killer (NK) cells directly in the tumor micro-environment and increase expression of PD-1 on these immune cells.

"We look forward to providing updates on NKTR-214, including the first data from the PIVOT trial evaluating NKTR-214 in combination with nivolumab, as well as updated data from the monotherapy trial of NKTR-214, including I-O naive RCC patients who received sequential checkpoint therapy following treatment with NKTR-214," said Mary Tagliaferri, M.D., Senior Vice President of Clinical Development at Nektar Therapeutics. "NKTR-214's unique mechanism which selectively increases tumor-killing TILs, combined with its favorable safety profile and clinical activity, support our combination trials of NKTR-214 with existing checkpoint inhibitors such as nivolumab and atezolizumab, as well as other immuno-oncology mechanisms in development."

NKTR-214 targets CD122 specific receptors found on the surface of cancer-fighting immune cells in order to stimulate their proliferation. In clinical and preclinical studies, treatment with NKTR-214 resulted in expansion of these cells and mobilization into the tumor micro-environment.1,2,3 NKTR-214 has an antibody-like dosing regimen similar to the existing checkpoint inhibitor class of approved medicines.

The abstracts published in advance of the ASCO meeting which were made available yesterday on the ASCO website at www.asco.org include preliminary data only as of February 7, 2017. Updated and additional patient data from these trials will be presented at ASCO.

Abstract 2545/Poster 37: "Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy."

Presenter: Chantale Bernatchez, Ph.D., The University of Texas MD Anderson Cancer Center

Poster Session: Developmental Therapeutics-Clinical Pharmacology and Experimental Therapeutics

Date and Time: Monday, June 5, 2017 - 8:00 a.m. - 11:30 a.m. CDT

Keywords for this news article include: Pharmaceutical Companies, Cancer, Oncology, Nektar Therapeutics, Biotechnology Companies.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
05/25 NEKTAR THERAPEUTICS : Announces Data Presentations at ASCO 2017
05/22 NEKTAR THERAPEUTICS : New Research Collaboration between Nektar and Takeda to Ex..
05/19 NEKTAR THERAPEUTICS (NASDAQ : NKTR) Files An 8-K Other Events
05/19 NEKTAR THERAPEUTICS : Other Events (form 8-K)
05/18 NEKTAR THERAPEUTICS : Announces Data Presentations at ASCO 2017
05/15 NEKTAR THERAPEUTICS : to Webcast Presentation at UBS Global Healthcare Conferenc..
05/11 NEKTAR THERAPEUTICS : Appoints Brian L. Kotzin, M.D. as Head of Clinical Develop..
05/10 NEKTAR THERAPEUTICS : Management's Discussion and Analysis of Financial Conditio..
05/09 NEKTAR THERAPEUTICS : reports 1Q loss
05/09 NEKTAR THERAPEUTICS : Results of Operations and Financial Condition, Financial S..
More news
Sector news : Biotechnology & Medical Research - NEC
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
05/23 Nektar Therapeutics (NKTR) Presents At UBS Global Healthcare Conference 2017 ..
05/22 Nektar and Takeda team up to explore anti-cancer potential of NKTR-214
05/13 Nektar Therapeutics' (NKTR) CEO Howard Robin On Q1 2017 Results - Earnings Ca..
05/09 Nektar Therapeutics misses by $0.01, misses on revenue
05/09 Showtime For Nektar Therapeutics
Financials ($)
Sales 2017 163 M
EBIT 2017 -141 M
Net income 2017 -183 M
Debt 2017 214 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 21,8x
EV / Sales 2018 18,5x
Capitalization 3 336 M
More Financials
Duration : Period :
Nektar Therapeutics Technical Analysis Chart | NKTR | US6402681083 | 4-Traders
Full-screen chart
Technical analysis trends NEKTAR THERAPEUTICS
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 24,9 $
Spread / Average Target 16%
Consensus details
EPS Revisions
More Estimates Revisions
Howard W. Robin President, Chief Executive Officer & Director
Robert B. Chess Chairman
John Nicholson Chief Operating Officer & Senior Vice President
Gilbert M. Labrucherie Chief Financial Officer & Senior Vice President
Stephen K. Doberstein Chief Scientific Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP AG23.45%15 409
CELLTRION, INC.--.--%10 281
More Results